Open Biosystems Helps Drexel University ''Knock Out'' Genes Associated with Alzheimer's Disease
Complete the form below to unlock access to ALL audio articles.
Open Biosystems, Inc. has announced that Drexel University is using its Expression Arrest™ shRNAmir retroviral library to identify and analyze genes associated with Alzheimer's disease.
By identifying the genes that are functionally associated with the disease, scientists will be able to develop therapies and potentially prevent the occurrence of the disease.
Gene knockdown through RNAi may enable scientists to develop a treatment that turns off genes that are responsible for the disease symptoms, thereby eliminating the disease before it begins.
Led by Dr. Aleister Saunders, the Alzheimer's study is in the final phase of a six-year process expected to be complete by end of the fall.
Taking advantage of short hairpin design, researchers are utilizing Open Biosystems' Expression Arrest shRNAmir retroviral library to help increase the efficiency and specificity of gene knockdown and reduce off-target effects.
Critical to the Alzheimer's study, Open Biosystems' shRNAmir library is designed to offer the ability to create stable gene knockdown in vitro.
"Expression Arrest shRNAmir is a truly revolutionary technology, and a fundamental tool for researchers looking to analyze gene function," said Dr. Saunders, professor of bioscience and biotechnology, Drexel University.
"We evaluated many different technologies and the shRNAmir technology was the ideal match for our project because of its affordability, comprehensive coverage of the human genome, multiple avenues of delivery to target cells and significant improvement to our efficiency in targeting genes."
"These qualities are allowing us, and many other investigators, to perform experiments that were previously impossible."
"Drexel University's use of our library exemplifies Open Biosystems' commitment to bringing the most comprehensive tools to academic institutions conducting critical research that holds the potential to significantly improve quality of life," said Troy Moore, CTO of Open Biosystems.
"We are able to provide scientists with access to the most critical RNAi resources without posing a burden on their bottom lines, enabling them to focus on developing technologies that will result in significant scientific breakthroughs."
In addition to the Alzheimer's disease study, the Expression Arrest shRNAmir retroviral library is distributed to 30 different scientists in 15 labs across Drexel's four campuses.
The distribution of these reagents is carried out by the Drexel University RNAi Resource Center.
These reagents are aiding Drexel scientists in the following research fields: aging, pharmacology and physiology, biomedical research, microbiology and immunology, biochemistry, general medicine, pulmonary medicine, pathology, surgery, laboratory medicine and cancer.
